UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health
A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.
ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings.
ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program.
Credit: UAB
BIRMINGHAM, Ala. - A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.
ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings.
ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program.
Resbiotic, Inc., a Bilmingham, Ala.-based biotech startup, raised $3M in seed funding.
The round was funded from a private equity syndicate led by Timberline Holdings. Braxton Goodrich (Timberline Holdings) will serve on the ResBiotic Board of Directors.
The company intends to use the funds for the development and commercialization of probiotic formulations for lung health.
ResBiotic is the flagship company of ResBiotech Innovation Institute, founded by physician scientist Dr. C Vivek Lal in 2020. ResBiotic’s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal’s Pulmonary Microbiome Lab at UAB with research and expertise from the university’s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development (TReNDD) program. The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company’s research and development
Share this article
Share this article
BIRMINGHAM, Ala., April 29, 2021 /PRNewswire/ University of Alabama at Birmingham s biotech startup Resbiotic, Inc. today announced a $3M seed round to support the development and commercialization of groundbreaking probiotic formulations for lung health. The round was funded from a private equity syndicate led by Timberline Holdings.
ResBiotic is the flagship company of ResBiotech Innovation Institute, founded by physician scientist Dr. C Vivek Lal in 2020. ResBiotic s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal s Pulmonary Microbiome Lab at UAB with research and expertise from the university s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development (TReNDD) program. The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company s research and development pipeline a
ResBiotic, Inc Raises $3M Seed Round and Announces Leadership Team prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.